Kyle’s practice focuses on mergers & acquisitions, including cross-border transactions, carve outs, joint ventures, divestitures and other complex corporate transactions. He has represented public and private companies across a diverse range of industries, and he has significant experience counseling clients on corporate governance and securities law matters.
SKIMS Acquires SKKN by Kim From Kim Kardashian and Coty
March 21, 2025
Cooley advised Kim Kardashian, an American media personality, socialite and businesswoman, on SKIMS’ acquisition of SKKN by Kim, a beauty, skincare, and fragrance brand she founded, including the 20% stake held by Coty.
Araris Biotech’s up to $1.14 Billion Acquisition by Taiho Pharmaceutical
March 17, 2025
Cooley advised Araris Biotech, a Swiss biotechnology company developing next-generation antibody-drug conjugates, on its definitive agreement to be acquired by Japan-based Taiho Pharmaceutical for up to $1.14 billion in cash.
Cooley Advises Special Committee of Checkpoint on Acquisition by Sun Pharma
March 9, 2025
Cooley advised the special committee of Checkpoint Therapeutics’ (Nasdaq: CKPT) board of directors in connection with Checkpoint’s definitive agreement to be acquired by Sun Pharmaceutical Industries (NSE: SUNPHARMA) for up to $416 million in cash and contingent value rights.
Cooley advised Katy Hearn and Haydn Schneider, co-founders of Alani Nu, in connection with Celsius Holdings’ (Nasdaq: CELH) definitive agreement to acquire the company for $1.8 billion in cash and stock.
Tempus Announces $600 Million Acquisition of Ambry Genetics
November 4, 2024
Cooley advised Tempus AI (Nasdaq: TEM), a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, on its agreement to acquire Ambry Genetics, a company focusing on genetic testing that aims to improve health by understanding the relationship between genetics and disease.
